Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
5.29
-0.01 (-0.19%)
Sep 4, 2025, 4:00 PM - Market closed
Evoke Pharma Employees
Evoke Pharma had 3 employees as of December 31, 2024. The number of employees decreased by 1 or -25.00% compared to the previous year.
Employees
3
Change (1Y)
-1
Growth (1Y)
-25.00%
Revenue / Employee
$4,264,953
Profits / Employee
-$1,794,103
Market Cap
11.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | -1 | -25.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | -1 | -20.00% |
| Dec 31, 2020 | 5 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EVOK News
- 8 days ago - MAI Capital Management Announces Strategic Partnership with Evoke Advisors - Business Wire
- 9 days ago - Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship - GlobeNewsWire
- 14 days ago - Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book - GlobeNewsWire
- 4 weeks ago - Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038 - GlobeNewsWire
- 2 months ago - Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036 - GlobeNewsWire
- 4 months ago - Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 - GlobeNewsWire
- 6 months ago - Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript - Seeking Alpha